Roivant Chief Executive Officer Matt Gline expects the FDA to approve the launch of a drug used to fight a debilitating skin disease. He says the drug should be on the market by September. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)
Roivant Chief Executive Officer Matt Gline expects the FDA to approve the launch of a drug used to fight a debilitating skin disease. He says the drug should be on the market by September. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/823e041680a0282d68fc3c00530d8785340ef646" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Roivant Expects FDA to Approve First Major Drug"></iframe>
